Updated on 24 August 2026
具有首创性治疗特应性皮肤炎的抗毒力药物
Commercial Director at Centre for Virology, Vaccinology and Therapeutics Limited
China (Hong Kong)
About
具有首创性治疗特应性皮肤炎的抗毒力药物,可抑制金黄色葡萄球菌的毒素和毒力产生,可治疗特应性皮炎及感染性伤口,药物通过抑制金黄色葡萄球菌的毒力,可从根源控制炎症及搔痒。
Project Location
- China (Hong Kong)
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
- Medical Technology
Total Project Value
- 25,000,001 to 50,000,000 USD
Investment Capital Required
- 5,000,001 to 7,500,000 USD
Interested Format of Cooperation
- Direct Equity Investment
Preferred Financing Model
- Equity
Type(s) of Last Financing Round of the project (if Applicable)
- Equity (private)
Main Service(s) Required
- Financial Services
Attached files
Similar opportunities
Project
- Yes
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Health Technology
- Equity (private)
- Medical Technology
- Financial Services
- Open for Negotiation
- 5,000,001 to 7,500,000 USD
- Feasibility Study Completed
- 25,000,001 to 50,000,000 USD
- Private Equity & Venture Capital
Roger Zhang
Commercial Director at Centre for Virology, Vaccinology and Therapeutics Limited
China (Hong Kong)
Project
Human Respiratory Organoid Platform & Applications
- Yes
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Health Technology
- Medical Technology
- Financial Services
- Open for Negotiation
- Direct Equity Investment
- 5,000,001 to 7,500,000 USD
- 1,000,001 to 2,500,000 USD
- Government & Public Funding
- Private Equity & Venture Capital
- Investment / Financing Discussion
Roger Zhang
Commercial Director at Centre for Virology, Vaccinology and Therapeutics Limited
China (Hong Kong)
Project
- No
- Yes
- Technology
- Operations
- Private Project
- Fund Management
- Financial Services
- Venture Capital (VC)
- Institutional Investment
- 10,000,001 to 25,000,000 USD
二盈 张
CEO at 深圳市金准生物医学工程有限公司
China